Statins and plaque stability

European Journal of Preventive Cardiology

Volumn 10, Issue 3, 2003, Pages 161-167

  Gomberg Maitland, Mardi ^a   Fuster, Valentin ^a   Fayad, Zahi Adel ^a   Badimon, Juan Jose ^a   Corti, Roberto ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

cardiovascular; plaque stability; statins

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; SODIUM PROTON EXCHANGE PROTEIN; THROMBOPLASTIN; THROMBOXANE; CD40 LIGAND; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CELL MEMBRANE FLUIDITY; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOGENICITY; VASCULAR ENDOTHELIUM; ENZYME INHIBITION; MORBIDITY; MORTALITY; NONHUMAN; THROMBOCYTE AGGREGATION INHIBITION;

ARTERIOSCLEROSIS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0038010369     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000071771.88247.cf     Document Type: Article

References (59)

1. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562–1569.
2. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140: 271–280. A comprehensive discussion on the influence of lipids and lipoproteins on thrombotic, fibrinolytic, and rheologic factors.
3. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41–46.
4. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94: 3090–3097.
5. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780–1787. A study elucidating the role of tissue factor as a thrombotic agent in plaque disruption.
6. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999; 100: 1215–1222. A study done in rabbits testing the hypothesis that lipid lowering reduces tissue factor expression and activity. Diminished activity was associated with a decreased expression of CD40L and CD40, a trigger of tissue factor expression by macrophages in human atheroma.
7. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265–272.
8. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, et al. Statins and cardiovascular diseases: The multiple effects of lipid lowering therapy by statins. Atherosclerosis 2000; 153: 181–189. A study done in hypercholesterolaemic patients testing two hypotheses. The first was that a reduction of plasma lipid levels with statins reduces blood thrombogenicity and endothelial dysfunction. Second, was that the decreased thrombogenicity of blood and endothelium was associated with a decreased number of circulating soluble adhesion molecules.
9. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, et al. Pravastatin: An anti-thrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688–692. A prospective six-month study of statin therapy illustrating that the diminished thrombogenicity provided by statin therapy was not proportional to the magnitude of LDL-C reduction. The study suggests that statins do more than diminish LDL-C and must have other affects causing the marked reduction in thrombogenicity.
10. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434–438.
11. van Willigen G, Gorter G, Akkerman JW. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 1994; 14: 41–46.
12. Le Quan Sang KH, Levenson J, Megnien JL, Simon A, Devynck MA. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolaemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759–764.
13. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolaemia. Arterioscler Thromb Vasc Biol 1995; 15: 247–251.
14. Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, et al. Platelet-dependent thrombin generation in patients with hyperlipidaemia. J Am Coll Cardiol 1997; 30: 91–96.
15. Lacoste L, Lam JYT Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolaemic coronary patients. J Am Coll Cardiol 1996; 27: 413A.
16. Sweetnam PM, Thomas HF, Yarnell JW, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur Heart J 1996; 17: 1814–1820.
17. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–641.
18. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolaemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991; 31: 512–517.
19. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475–1481.
20. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 1995; 18: 261–267.
21. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989; 86: 3847–3851.
22. Koenig W, Hehr R, Ditschuneit HH, Kuhn K, Ernst E, Rosenthal J, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: Dependence on lipoprotein (a)? J Clin Pharmacol 1992; 32: 539–545.
23. Mayer J, Eller T, Brauer P, Solleder EM, Schafer RM, Keller F, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196–201.
24. Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997; 18: 235–241.
25. DiCorleto P, Gimbrone MA. Vascular endothelium. In: Fuster V, Ross R, Topol ES (editors): Atherosclerosis and coronary artery disease. Vol. 1 Philadelphia: Lippincott-Raven; 1996 p. 387.
26. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046–1051.
27. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319–324.
28. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–1135.
29. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–691.
30. Fuster V. Plaque Stabilization. In: Fuster V (editors): The vulnerable atherosclerotic plaque: understanding, identification, and modification. Armonk, NY: Futura Publishing Company Inc.; 1999 pp. 393–412.
31. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation 1994; 89: 2519–2524.
32. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–1131.
33. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential non-invasive marker of healing coronary endothelium. Circulation 1994; 89: 1530–1538.
34. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A–125A.
35. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease [see comments]. Circulation 1997; 95: 324–328.
36. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 1996; 94: 1503–1505.
37. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775–778.
38. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850. A comprehensive review detailing the molecular mechanisms of acute coronary syndromes.
39. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: Biology. Lancet 1999; 353: 5–9. An extensive review of the biological phenomena causing acute coronary syndromes. The article explains the molecular mechanisms and correlates them with clinical syndromes. Future therapies with apoptotic and tissue factor inhibitors and the role of new imaging technologies are explored.
40. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565–1569.
41. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation 1998; 97: 2433–2444.
42. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062–1072.
43. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism 1992; 41: 229–235.
44. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolaemic rats. Arterioscler Thromb Vasc Biol 1997; 17: 1521–1526.
45. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolaemia. J Am Coll Cardiol 1997; 30: 1212–1217.
46. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259–268.
47. Martin AJ, Gotlieb AI, Henkelman RM. High-resolution MR imaging of human arteries. J Magn Reson Imaging 1995; 5: 93–100.
48. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996; 94: 932–938.
49. Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol 1999; 19: 2756–2761.
50. Fayad ZA, Nahar T, Fallon JT, Goldman M, Aguinaldo JG, Badimon JJ, et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: A comparison with transesophageal echocardiography. Circulation 2000; 101: 2503–2509. An in vivo study using MR imaging evaluating atherosclerotic plaque size, extent and composition in human thoracic aorta. The study demonstrates the power and utility of MR imaging of atherosclerotic disease.
51. Fayad Z, Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. Annals of the New York Academy of Science 2000; 902: 173–186.
52. Fayad ZA, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G, et al. Non-invasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation 2000; 102: 506–510. An in vivo study using MR imaging demonstrated improved plaque characterization in human coronary arteries. MR imaging allows evaluation of plaque content and may become a useful diagnostic tool for detection of vulnerable lesions.
53. van der Wall EE, Vliegen HW, de Roos A, Bruschke AV. Magnetic resonance imaging in coronary artery disease. Circulation 1995; 92: 2723–2739.
54. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen re-narrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolaemic Yucatan micropig. Circulation 1994; 89: 2816–2821.
55. Small DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988; 8: 103–129.
56. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998; 339: 1972–1978.
57. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid-lowering by simvastatin induces regression of human atherosclerotic lesions: 2 years follow-up by high resolution noninvasive MRI. Circulation 2002; 106: 2884–2887.
58. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279: 1643–1650.
59. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–1082.